Cargando…
Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition
Modulation of the immune system for the treatment of primary and metastatic tumors has been a goal of cancer research for many years. The E3 ubiquitin ligase Cbl-b has been established as an intracellular checkpoint that limits T cell activation, critically contributing to the maintenance of self-to...
Autores principales: | Peer, Sebastian, Baier, Gottfried, Gruber, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522032/ https://www.ncbi.nlm.nih.gov/pubmed/28611299 http://dx.doi.org/10.18632/oncotarget.18360 |
Ejemplares similares
-
Tumor rejection in Cblb(−/−) mice depends on IL-9 and Th9 cells
por: Schanz, Oliver, et al.
Publicado: (2021) -
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016) -
T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy
por: Bruns, Michael, et al.
Publicado: (2016) -
Adoptive Transfer of siRNA Cblb-Silenced CD8(+) T Lymphocytes Augments Tumor Vaccine Efficacy in a B16 Melanoma Model
por: Hinterleitner, Reinhard, et al.
Publicado: (2012) -
Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)